Reply to Raoult and Rolain, and to Echols and Tillotson
- PMID: 30839092
- PMCID: PMC6792094
- DOI: 10.1093/cid/ciz186
Reply to Raoult and Rolain, and to Echols and Tillotson
Comment on
-
Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents.Clin Infect Dis. 2018 Nov 28;67(12):1803-1814. doi: 10.1093/cid/ciy378. Clin Infect Dis. 2018. PMID: 30052813 Free PMC article.
-
The Paradigm of the Shadoks and Antibiotic Resistance.Clin Infect Dis. 2019 Oct 15;69(9):1641. doi: 10.1093/cid/ciz183. Clin Infect Dis. 2019. PMID: 30838399 No abstract available.
-
Difficult to Treat: Do We Need a New Definition?Clin Infect Dis. 2019 Oct 15;69(9):1641-1642. doi: 10.1093/cid/ciz184. Clin Infect Dis. 2019. PMID: 30838418 No abstract available.
References
-
- Raoult D, Rolain J. The paradigm of the Shadoks and antibiotic resistance. Clin Infect Dis 2019; 69:1641. - PubMed
-
- Tillotson S, Echols R. DTR, do we need a new definition? Clin Infect Dis 2019; 69:1641–2. - PubMed
-
- Kadri SS, Adjemian J, Lai YL, et al. ; National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI) Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis 2018; 67:1803–14. - PMC - PubMed
-
- CDC. Antibiotic resistance patient safety Atlas. 2018. Available at: https://www.cdc.gov/hai/data/portal/patient-safety-atlas.html. Accessed 14 March 2019.
-
- Abat C, Rolain JM, Dubourg G, Fournier PE, Chaudet H, Raoult D. Evaluating the clinical burden and mortality attributable to antibiotic resistance: the disparity of empirical data and simple model estimations. Clin Infect Dis 2017; 65:58–63. - PubMed